On the Mechanism of Coagulation Inhibition on Surfaces with End Point Immobilized Heparin

Summary

A well established technique to improve blood compatibility of artificial materials for use in the circulation is to coat the surface with heparin. The present report describes the antithrombin mediated inhibition of thrombin and factor Xa by surfaces modified with end point immobilized heparin. The reaction was followed by conventional chromogenic substrate based enzyme assays as well as by immunological measurement of the enzyme inhibitor (thrombin-antithrombin) complex formation. Both enzymes were rapidly inactivated by heparin surfaces after selective presaturation with antithrombin on the immobilized high affinity heparin molecules. The thrombin inhibitory capacity was enhanced when both high and low affinity heparin were preadsorbed with inhibitor. The main part of the thrombin-antithrombin complex formed remained bound to the surface, however, without functionally blocking the activity of the high affinity sequence of the immobilized heparin.

Aliquots of recalcified plasma were slowly rotated in loops of heparinized tubing to investigate whether the main thromboresistant function of the surface was exerted at the level of thrombin or by inactivation of preceding enzymes. After 1 h no visible clotting occurred and only trace amounts of thrombin (0.07 IU/ml), measured as thrombin-antithrombin complexes, had been formed. In non-heparinized loops and in the test tube plasma clotted after 20 min. The thrombin generation when clotting occurred was in the order of 10 IU/ml. It is concluded that the immobilized heparin mediates inhibition of the coagulation cascade prior to prothrombin activation.

• References

• 1 Larm O, Larsson R, Olsson R. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified, reducing terminal residue. Biomat Med Dev Art Org 1983; 11: 161-163
• 2 Bindslev L, Gouda I, Inacio J, Kodama K, Lagergren H, Larm O, Nilsson E, Olsson R. Extracorporeal elimination of carbon dioxide using a surface-heparinized veno-venous by-pass system. Trans Am Soc Artif Intern Org 1986; 32: 530-533
• 3 Koul B, Vestergirst O, Egberg N, Steen S. Twenty-four hours heparin free veno-right ventricular ECMO - An experimental study. J Thorac Cardiovasc Surg. In press
• 4 Mottaghy K, Oedekoven B, Pöppel K, Bruchmuller K, Kovacs B, Spahn A, Geisen C. Heparin free long-term extracorporeal circulation using bioactive surfaces. Trans Am Soc Intern Org 1989; 35: 635-639
• 5 Bindslev L, Eklund J, Norlander O, Swedenborg J, Olsson P, Inacio J, Nilsson E, Larm O, Gouda I, Malmberg A, Scholander E. Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung. Anesthesiology 1987; 67: 117-120
• 6 Bindslev L, Böhn C, Jolin Ö, Hambraeus JonzonK, Olsson P, Rynak S. Extracorporeal carbon dioxide removal performed with surface-heparinized equipment in patients with ARDS. Acta Anaesth Scand. In press
• 7 Kodama K, Pasche B, Olsson P, Swedenborg J, Adolfsson L, Larm O, Riesenfeld J. Antithrombin III binding to surface immobilized heparin and its relation to Factor Xa inhibition. Thromb Haemostas 1987; 58: 1064-1067
• 8 Pasche P, Elgue G, Olsson P, Riesenfeld J, Rasmuson A. Binding of antithrombin to immobilized heparin under varying flow conditions. Art Org 1991; 15: 481-491
• 9 Pasche B, Kodama K, Larm O, Olsson P, Swedenborg J. Thrombin inhibition with covalently bonded heparin. Thromb Res 1986; 44: 739-748
• 10 Bertilsson L, Elwing H, Liedberg B, Larm O, Riesenfeld J, Scholander E. Infrared characterization of complex sandwich structures: heparin immobilized in polyethylene surfaces. Mol Eng 1991; 1: 49-57
• 11 Elgue G, Sanchez J, Egberg N, Olsson P, Riesenfeld J. Effect of surface immobilized heparin on the activation of adsorbed FXII. Art Org. In press
• 12 Elgue G, Pasche B, Blombäck M, Olsson P. The use of a commercial ELISA for assay of thrombin-antithrombin complexes in purified systems. Thromb Haemostas 1990; 63: 435-438
• 13 Nordenman B, Nordling K, Björk I. A differential effect of lowaffinity heparin on the inhibition of thrombin and factor Xa by antithrombin. Thromb Res 1979; 17: 595-600
• 14 Nordenman B, Björk I. Studies on the binding of heparin to prothrombin and thrombin and the effect of heparin binding on thrombin activity. Thromb Res 1978; 12: 755-765
• 15 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 16 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton IIJW, Blajchamn MA. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150
• 17 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400
• 18 Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74: 341-350
• 19 Mollnes TE, Videm V, Götze M, Harbor M, Oppermann M. Formation of C5a during cardiopulmonary bypass: inhibition of precoating with heparin. Ann Thorac Surg 1991; 52: 92-97
• 20 Videm V, Mollnes TE, Garred P, Aasen AO, Svennevig JL. Biocompatibility of extracorporeal circulation: in vitro comparison of heparin coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101: 654-660
• 21 Videm V, Svennevig JL, Fosse E, Semb D, Österud A, Mollness TE. Reduced complement activation with heparin-coated oxygenator and tubing in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 809-813